NCT06255626View on ClinicalTrials.gov

Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

215

Participants

Timeline

Start Date

May 27, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions

COVID-19

Interventions

DRUG

CD40.RBDv vaccin (SARS-Cov2 Vaccin)

1 or 2 injection(s) of CD40.RBDv vaccine (or mRNA vaccine 1 injection (5:1))

Trial Locations (2)

75014

RECRUITING

Hôpital Cochin, Paris

94000

RECRUITING

Hopital Henri Mondor, Créteil

All Listed Sponsors

collaborator

Vaccine Research Institute (VRI), France

UNKNOWN

collaborator

EnnoDc (previously known as LinKinVax)

UNKNOWN

lead

ANRS, Emerging Infectious Diseases

OTHER_GOV

NCT06255626 - Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers. | Biotech Hunter | Biotech Hunter